Jpmorgan Chase & CO Eledon Pharmaceuticals, Inc. Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
A detailed history of Jpmorgan Chase & CO transactions in Eledon Pharmaceuticals, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 97 shares of ELDN stock, worth $401. This represents 0.0% of its overall portfolio holdings.
Number of Shares
97
Previous 91
6.59%
Holding current value
$401
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding ELDN
# of Institutions
34Shares Held
18.4MCall Options Held
0Put Options Held
0-
Bvf Inc San Francisco, CA6.29MShares$26.1 Million0.5% of portfolio
-
Armistice Capital, LLC New York, NY2.36MShares$9.79 Million0.1% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.57MShares$6.48 Million0.0% of portfolio
-
Schonfeld Strategic Advisors LLC New York, NY1.5MShares$6.21 Million0.03% of portfolio
-
Zimmer Partners, LP New York, NY1.43MShares$5.94 Million0.07% of portfolio
About Eledon Pharmaceuticals, Inc.
- Ticker ELDN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 13,756,800
- Market Cap $57M
- Description
- Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that i...